Diverse avenues of research support the transmethylation theory of psychosis: implications for neuroprotection
Christine L. Miller
Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (3) : 198 -239.
Transmethylation in the context of psychiatry has historically referred to the enzymatic transfer of a methyl group from one biochemical to another, whose resulting function can change so dramatically that a biochemical like tryptamine, for example, is converted into the hallucinogen dimethyltryptamine. Central to endogenous methylation activity is the folate cycle, which generates the primary transferable methyl groups in mammalian biochemistry. The relevance of this cycle to mental health becomes clear when the cycle is dysregulated, often leading to a buildup of both homocysteine and S-adenosylhomocysteine (SAH), while accompanied by a transient reduction in the intended physiologic target, S-adenosylmethionine (SAM). This paper includes an in-depth review of the causes of folate cycle perturbations associated with psychotic symptoms, expounding on alternative downstream pathways which are activated and pointing toward potential etiologic agents of the associated psychosis, the methylated tertiary amines N-methyl-salsolinol, N-methyl-norsalsolinol, and adrenochrome, which appear in scientific reports concerning their association with hallucinogenic and/or neurotoxic outcomes. Electrotopological state (E-state) data has been generated for these compounds, illustrating a strong similarity with hallucinogens, particularly in terms of the E-state of the nitrogen in their tertiary amine moieties. In light of the role the folate cycle plays in transmethylation, neuroprotective strategies to prevent the transition to psychosis are suggested, including the advisory that folate supplementation can be harmful depending on the status of other relevant biochemicals.
hallucinogens / psychotic disorders / folate cycle / homocysteine / vitamin B12 / Folfirinox / MTHFR / electrotopology
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
Ebara S. Nutritional role of folate. Congenit Anom (Kyoto). 2017; 57: 138-41. |
| [8] |
Milman N. Intestinal absorption of folic acid - new physiologic & molecular aspects. Indian J Med Res. 2012; 136: 725-8. |
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
Zhu BT. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol. 2002; 17: 1283-91. |
| [14] |
|
| [15] |
Doherty GH. Homocysteine and Parkinson’s Disease: A Complex Relationship. J Neurol Disord. 2013; 1: 107. |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
Lizano P, Pong S, Santarriaga S, Bannai D, |
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
Elayan H, Kennedy B, |
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
Miller CL. The chemical interaction between adrenochrome, three different classes of antipsychotic drugs and metabolites of the kynurenine pathway. Eur Neuropsychopharmacol. 2015; 25: 435-40. |
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
Smythies J. The adrenochrome hypothesis of schizophrenia revisited. Neurotox Res. 2002; 4: 147-50. |
| [73] |
Miller CL. On the mechanism of action of antipsychotic drugs: a chemical reaction not receptor blockade. Curr Drug Discov Technol. 2013; 10: 195-208. |
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
Trimmer EE. Methylenetetrahydrofolate reductase: biochemical characterization and medical significance. Curr Pharm Des. 2013; 19: 2574-93. |
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
Sandler M, Carter SB, Hunter KR, Stern GM. Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man. Nature. 1973; 241: 439-43. |
| [85] |
|
| [86] |
Martinez-Alvarado P, Dagnino-Subiabre A, Paris I, Metodiewa D, |
| [87] |
Kobayashi H, Fukuhara K, Tada-Oikawa S, Yada Y, Hiraku Y, Murata M, |
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
Xie G, Krnjević K, |
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
Lanz J, Biniaz-Harris N, Kuvaldina M, Jain S, Lewis K, Fallon BA. Disulfiram: Mechanisms, Applications, and Challenges. Antibiotics (Basel). 2023; 12: 524. |
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
Yamanaka Y. Effect of salsolinol on rat brain and liver monoamine oxidase. Jpn J Pharmacol. 1971; 21: 833-6. |
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
Reynolds EH. Benefits and risks of folic acid to the nervous system. J Neurol Neurosurg Psychiatry. 2002; 72: 567-71. |
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
Shay H, |
| [147] |
|
| [148] |
|
| [149] |
|
| [150] |
|
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
Fora A, Alabsi E, |
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
|
| [166] |
Shakya S, Shrestha S, |
| [167] |
|
| [168] |
|
| [169] |
|
| [170] |
|
| [171] |
|
| [172] |
|
| [173] |
Bertino JR. Nutrients, vitamins and minerals as therapy. Cancer. 1979; 43: 2137-42. |
| [174] |
|
| [175] |
|
| [176] |
|
| [177] |
|
| [178] |
Rummel T, Suormala T, Häberle J, Koch HG, Berning C, Perrett D, |
| [179] |
|
| [180] |
|
| [181] |
|
| [182] |
|
| [183] |
|
| [184] |
Suormala T, Gamse G, Fowler B. 5,10-Methylenetetrahydrofolate reductase (MTHFR) assay in the forward direction: residual activity in MTHFR deficiency. Clin Chem. 2002; 48: 835-43. |
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
|
| [189] |
|
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
|
| [194] |
|
| [195] |
|
| [196] |
|
| [197] |
|
| [198] |
|
| [199] |
|
| [200] |
|
| [201] |
|
| [202] |
|
| [203] |
|
| [204] |
|
| [205] |
|
| [206] |
Rai V. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene and susceptibility to depression in Asian population: a systematic meta-analysis. Cell Mol Biol (Noisy-le- grand). 2014; 60: 29-36. |
| [207] |
|
| [208] |
|
| [209] |
|
| [210] |
|
| [211] |
|
| [212] |
|
| [213] |
dos Reis FP, Duarte L, Cartaxo T, Santos V. Folic acid, vitamin B12, and psychotic symptoms among young psychiatric inpatients. Nascer e Crescer. 2021;30:85-91. |
| [214] |
|
| [215] |
Frajerman A, Urban M, Rivollier F, Plaze M, Chaumette B, Krebs MO, |
| [216] |
|
| [217] |
|
| [218] |
Michot JM, Sedel F, Giraudier S, Smiejan JM, Papo T. Psychosis, paraplegia and coma revealing methylenetetrahydrofolate reductase deficiency in a 56-year-old woman. J Neurol Neurosurg Psychiatry. 2008;79:963-4. |
| [219] |
|
| [220] |
|
| [221] |
|
| [222] |
|
| [223] |
|
| [224] |
|
| [225] |
|
| [226] |
|
| [227] |
|
| [228] |
|
| [229] |
|
| [230] |
Martone G. Enhancement of recovery from mental illness with l-methylfolate supplementation. Perspect Psychiatr Care. 2018; 54: 331-4. |
| [231] |
Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, |
| [232] |
|
| [233] |
|
| [234] |
|
| [235] |
|
| [236] |
|
| [237] |
|
| [238] |
|
| [239] |
|
| [240] |
|
| [241] |
Geddes JR, Gardiner A, Rendell J, Voysey M, Tunbridge E, Hinds C, |
| [242] |
|
| [243] |
|
| [244] |
|
| [245] |
|
| [246] |
|
| [247] |
|
| [248] |
|
| [249] |
|
| [250] |
|
| [251] |
|
| [252] |
|
| [253] |
|
| [254] |
|
| [255] |
|
| [256] |
|
| [257] |
Abi-Dargham A, |
| [258] |
|
| [259] |
Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, |
| [260] |
|
| [261] |
|
| [262] |
|
| [263] |
Jacob P 3rd, |
| [264] |
|
| [265] |
|
| [266] |
|
| [267] |
|
| [268] |
|
| [269] |
|
| [270] |
|
| [271] |
|
| [272] |
|
| [273] |
Ivanciuc O. Electrotopological State Indices. In: Mannhold R, editor. Molecular Drug Properties: Measurement and Prediction. Wiley; 2007. pp. 85-109. |
| [274] |
|
| [275] |
|
| [276] |
|
| [277] |
|
| [278] |
|
| [279] |
|
| [280] |
|
| [281] |
|
| [282] |
Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, |
| [283] |
|
| [284] |
|
| [285] |
Hoffman A. LSD: My Problem Child. MAPS: Open Books; 2005. |
| [286] |
|
| [287] |
|
| [288] |
|
| [289] |
|
| [290] |
|
| [291] |
|
| [292] |
|
| [293] |
|
| [294] |
|
| [295] |
|
| [296] |
|
| [297] |
|
| [298] |
|
| [299] |
|
/
| 〈 |
|
〉 |